Eris Lifesciences Limited

11%

BUSINESS AND FINANCIAL HIGHLIGHTS – Q1 FY26 • Domestic Branded Formulations (DBF) business grows 11% - outperforms IPM* by ~ 330 bps • Domestic Branded Formulations (DBF) business grows 11% - outperfo

330 bps

HLIGHTS – Q1 FY26 • Domestic Branded Formulations (DBF) business grows 11% - outperforms IPM* by ~ 330 bps • Domestic Branded Formulations (DBF) business grows 11% - outperforms IPM* by - 330 bps • DBF gro

14%

ic Branded Formulations (DBF) business grows 11% - outperforms IPM* by - 330 bps • DBF growth ~ 13-14% after excluding impact from discontinued FDCs and insulin shortages • DBF growth - 13-14% after exc

155 bps

after excluding impact from discontinued FDCs and insulin shortages • DBF operating margin expands 155 bps yoy to 37% - post addition of 300+ MRs • DBF operating margin expands 155 bps yoy to 37% - post add

37%

impact from discontinued FDCs and insulin shortages • DBF operating margin expands 155 bps yoy to 37% - post addition of 300+ MRs • DBF operating margin expands 155 bps yoy to 37% - post addition of 30

30%

yoy to 37% - post addition of 300+ MRs • Value creation in Biocon business continues; Q1 margin ~ 30% up from 19% at acquisition • Value creation in Biocon business continues; Q1 margin - 10% up from 1

19%

- post addition of 300+ MRs • Value creation in Biocon business continues; Q1 margin ~ 30% up from 19% at acquisition • Value creation in Biocon business continues; Q1 margin - 10% up from 19% at acquis

10%

margin ~ 30% up from 19% at acquisition • Value creation in Biocon business continues; Q1 margin - 10% up from 19% at acquisition • EPS acceleration kicks off as per guidance, with a 41% PAT/ EPS growt

41%

s; Q1 margin - 10% up from 19% at acquisition • EPS acceleration kicks off as per guidance, with a 41% PAT/ EPS growth in the quarter • EPS acceleration kicks off as per guidance, with a 41% PAT/ EPS gr

Rs. 5

rowth in the quarter • We are ramping down the Trade Gx division; took an EBIDTA loss (ex. DBF) of Rs. 5+ cr. in Q1 • We are ramping down the Trade Gx division; took an EBIDTA loss (ex. DBF) of Rs. 1-1- c

Rs. 1

) of Rs. 5+ cr. in Q1 • We are ramping down the Trade Gx division; took an EBIDTA loss (ex. DBF) of Rs. 1-1- cr. in Q1 • After significant delays, we have commenced the manufacturing of insulin vials at B

65%

rtunity expected to accrue starting Nov/Dec '25 • OCF-to-EBIDTA ratio from continuing operations ~ 65% - post adjustment for strategic • OCF-to-EBIDTA ratio from continuing operations - 65% - post adju